Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France

2022 ◽  
Author(s):  
Montserrat Roset ◽  
Mayur Amonkar ◽  
Renna Patel ◽  
Núria Lara ◽  
Smita Kothari
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Standard Of Care ◽  
Treatment Patterns ◽  
Review Study

scholarly journals Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real‐World Settings: A Multicenter Retrospective Chart Review Study

2019 ◽  
Vol 24 (8) ◽  
pp. 1066-1075
Author(s):  
Arvind Dasari ◽  
Emily K. Bergsland ◽  
Al B. Benson ◽  
Beilei Cai ◽  
Lynn Huynh ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Neuroendocrine Tumors ◽  
Real World ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Treatment Patterns ◽  
Review Study

scholarly journals Real‐World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study

2019 ◽  
Vol 24 (8) ◽  
pp. 1056-1065
Author(s):  
Matthew H. Kulke ◽  
Al B. Benson ◽  
Arvind Dasari ◽  
Lynn Huynh ◽  
Beilei Cai ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Neuroendocrine Tumors ◽  
Real World ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Treatment Patterns ◽  
Review Study

scholarly journals Advanced melanoma treatment patterns in the modern era: United Kingdom (UK) real world retrospective chart review study

2018 ◽  
Vol 29 ◽  
pp. viii459
Author(s):  
J.J. Sacco ◽  
P.G. Corrie ◽  
O. Oladipo ◽  
M. Payne ◽  
J. Larkin ◽  
...  
Keyword(s):  
United Kingdom ◽  
Real World ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Treatment Patterns ◽  
Advanced Melanoma ◽  
Melanoma Treatment ◽  
Review Study ◽  
Modern Era

Real-world treatment patterns and outcomes in hepatorenal syndrome: results from a retrospective chart review study in the United Kingdom

2020 ◽  
Vol 73 ◽  
pp. S731-S732
Author(s):  
Kevin Moore ◽  
Khurram Jamil ◽  
Katharina Verleger ◽  
Linlin Luo ◽  
Nehemiah Kebede ◽  
...  
Keyword(s):  
United Kingdom ◽  
Real World ◽  
Chart Review ◽  
Hepatorenal Syndrome ◽  
Retrospective Chart Review ◽  
Treatment Patterns ◽  
The United Kingdom ◽  
Review Study

Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 102-102
Author(s):  
Mayur Amonkar ◽  
David Gomez-Ulloa ◽  
Smita Kothari ◽  
Winson Y. Cheung ◽  
Ian Chau ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Clinical Outcomes ◽  
Real World ◽  
Retrospective Chart Review ◽  
Progression Free Survival ◽  
Standard Of Care ◽  
Patient Characteristics ◽  
Metastatic Gastric Cancer ◽  
Treatment Patterns ◽  
Randomised Controlled

102 Background: Despite increased survival demonstrated for patients with advanced / metastatic GC due to 2L chemotherapy, different standard of care options exist. This study aims to describe RW treatment patterns and clinical outcomes in patients with advanced / metastatic GC receiving 2L treatment. Methods: Retrospective chart review study conducted in Australia, Canada, Italy and UK. Patients diagnosed with metastatic / unresectable GC receiving 2L treatment between January 2013 and July 2015 were enrolled. Patient characteristics, treatment patterns and clinical outcomes were captured for 12 months from the start of 2L treatment or until death. Results: 280 patients were included (mean age 60.9 years, 68.9% male). Half of the patients (51.8%) received monotherapy in 2L. Among these, taxanes were most prescribed (69.0%) followed by irinotecan (22.1%). Doublet chemotherapy was the most common combination therapy in 2L (75.6%) with fluoropyrimidine + irinotecan (33.3%) being the most used, followed by fluoropyrimidine + platinum (17.8%). Less than a third of patients (29.3%) received subsequent third-line (3L) treatment; 62.7% received monotherapy [mainly taxanes (69.2%) or irinotecan (19.2%)]. Most 3L patients who had combination therapy received a doublet (86.7%), most frequently fluoropyrimidine combined with irinotecan (53.3%) or platinum (20.0%). The majority of 2L patients (93.6%) had received combination therapy as first-line treatment, of whom 67.9% had received triplet chemotherapy, most commonly anthracycline + fluoropyrimidine + platinum (51.1%). Estimated median real-world progression free survival (PFS) and overall survival (OS) after 2L treatment initiation was 3.09 (95% CI: 2.76-3.68) and 6.54 (5.29-7.76) months, respectively, and estimated probability of PFS and OS at 12 months was 8% and 26%, respectively. Conclusions: The clinical management of advanced / metastatic GC patients in 2L treatment commonly involves taxanes or irinotecan as monotherapy, or irinotecan or platinum-based combinations with fluoropyrimidines. RW clinical outcomes for 2L treatment are similar to randomised controlled trials but remain poor.

scholarly journals Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study

Medicina ◽  
2021 ◽  
Vol 57 (11) ◽  
pp. 1233
Author(s):  
Eriko Hiruta ◽  
Yukiyoshi Fujita ◽  
Hisao Imai ◽  
Takashi Masuno ◽  
Shigeki Yamazaki ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Adverse Events ◽  
Real World ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Treatment Patterns ◽  
Poor Performance Status ◽  
Patients With Cancer ◽  
Review Study

Background and Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist that improves opioid-induced constipation. Although clinical trials have excluded patients with poor performance status (PS) and those started on naldemedine early after opioid initiation, clinical practice has used naldemedine for the same patients. Therefore, we investigated the treatment patterns of naldemedine in a real-world setting. Materials and Methods: This was a multicenter, retrospective chart review study of opioid-treated patients with cancer receiving naldemedine. Adverse events that occurred within 7 days of naldemedine initiation were evaluated in those who received one or more doses of the same. Effectiveness was assessed in patients who used naldemedine for more than 7 days. Results: A total of 296 patients satisfied the eligibility criteria, among whom 129 (43.6%) had a PS of ≥3 and 176 (59.5%) started naldemedine within 2 weeks of opioid initiation. Moreover, 203 (79.6%) patients had ≥3 bowel movements per week. Incidences of all grades of diarrhea and abdominal pain were 87 (29.4%) and 12 (4.1%), respectively. No patient had grade 4 or higher adverse events. Conclusions: Although nearly half of the patients receiving naldemedine in clinical practice belonged to populations that were not included in the clinical trials, our results suggested that naldemedine in clinical practice had the same efficacy and safety as that in clinical trials.

scholarly journals Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 795-795
Author(s):  
Christopher R Frei ◽  
Hannah Le ◽  
Daniel McHugh ◽  
Cynthia Elesinmogun ◽  
Samantha Galley ◽  
...  
Keyword(s):  
Dose Reduction ◽  
Real World ◽  
Chart Review ◽  
Treatment Initiation ◽  
Treatment Patterns ◽  
Novel Agents ◽  
Major Bleed ◽  
The Us ◽  
Review Study

Introduction : CLL is the most common chronic leukemia in the US, with nearly 20,000 new cases expected annually. Novel agents, such as ibrutinib, idelalisib, and venetoclax, have been approved in recent years and provide oral options for CLL. However, there is limited data regarding real-world treatment patterns with these novel agents. This study describes dose reduction and discontinuation rates, reasons for both, and outcomes, including overall survival (OS) and duration of therapy (DOT), in CLL patients treated with novel agents. Methods : This is an analysis of a large retrospective cohort study of adult patients (≥ 18 years old) with CLL, treated with novel agents in the VHA from 10/01/2013 to 3/31/2018. Historical data were examined for up to 20 years prior to the enrollment period (10/01/1993 to 9/30/2013). Index date was defined as the date of novel agent initiation. The follow-up period was a minimum of 6 months post index date. Variables, collected via a structured EMR database, included patient demographics, and clinical and treatment characteristics. CLL diagnosis, molecular profiles, and reasons for dose reduction and discontinuation were abstracted by chart review. Descriptive statistics were used to summarize baseline characteristics, treatment patterns, and outcomes. Results: A total of 1205 CLL patients were included in this analysis. Of these, in first observed line, 328 (27%) patients received ibrutinib; in relapsed/refractory observed line (r/r), 741(62%) patients received ibrutinib, 49 (4%) patients on idelalisib, and 87 (7%) patients on venetoclax. Ibrutinib patients in first observed line had a median (range) age of 73 (48-96) years and a median follow-up of 23 (3-54) months after treatment initiation. Dose reduction (n=83, 25%) and discontinuation (n=108, 33%) were frequently due to adverse events (AEs) (93% and 64%). Median DOT to ibrutinib discontinuation was 8 months. The most common AEs leading to dose reduction were major bleed (15%) and rash (15%). The most common AEs leading to discontinuation were atrial fibrillation (20%), major bleed (19%), and infection (11%). The calculated median OS from initiation was 31 (14-49) months. R/R ibrutinib patients had a median age of 72 (45-96) years and had 31 (2-85) months of follow-up after treatment initiation. Dose reduction (n=242, 33%) and discontinuation (n=263, 35%) were frequently due to AEs (89% and 63%). Median DOT to ibrutinib discontinuation was 12 months. The most common AEs leading to dose reduction were thrombocytopenia (13%), arthralgia/myalgia (13%), and infection (12%). The most common AEs leading to discontinuation were atrial fibrillation (19%), infection (15%), and major bleed (11%). the calculated median OS from initiation was 39 (9-57) months. R/R idelalisib patients (n=49) had a median age of 72 (55-93) years and had 27 (3-53) months of follow-up after treatment initiation. Dose reduction (n=8, 16%) and discontinuation (n=41, 84%) were frequently due to AEs (100% and 54%). Median DOT to idelalisib discontinuation was 5 months. The most common AE leading to dose reduction was neutropenia (50%). The most common AEs leading to discontinuation were infection (27%) and pneumonia (18%). R/R venetoclax patients (n=87) had a median age of 72 (47-90) years and had 9 (0-35) months of follow-up after treatment initiation. Dose reduction (n=24, 28%) and discontinuation (n=27, 31%) were frequently due to AEs (100% and 41%). Median DOT to venetoclax discontinuation was 5 months. The most common AEs leading to dose reduction were neutropenia (27%) and thrombocytopenia (27%). The most common AEs leading to discontinuation were neutropenia (36%), thrombocytopenia (18%), and infection (18%). There was not enough follow-up time to have a meaningful OS in this cohort. Conclusions: To our knowledge, this is the largest EMR/chart review study among CLL patients initiating treatments in the real-world setting. This study provides evidence regarding patient characteristics, treatment patterns, and outcomes among patients initiating novel agents for the treatment of CLL in the national VHA population. Dose reduction and discontinuation were frequent across all novel agents, with AEs as the most common reason. These data highlight the significant difference in real world data compared with clinical trial data and indicate the unmet need for more tolerable treatment options for CLL patients. Disclosures Frei: AstraZeneca: Research Funding. Le:AstraZeneca: Employment, Other: Stocks. McHugh:AstraZeneca: Employment. Elesinmogun:AstraZeneca: Employment, Equity Ownership. Obodozie-Ofoegbu:UT Austin: Employment.

Sign in / Sign up

Export Citation Format

Share Document